BDBM417004 (+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropylmethylamino)(pyridin-4-yl)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide::US10329260, Compound 265d::US10633345, Compound 264g::US10689346, Compound 264g::US11203574, Compound 264g::US11230530, Compound 264g::US11685721, Compound 264g::US11708332, Compound 264g

SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccncc1)C(F)(F)F

InChI Key InChIKey=UQWHIYYZYLIMKJ-UHFFFAOYSA-N

Data  15 KI

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 417004   

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
1/10/2021
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
2/22/2021
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
5/29/2022
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
4/29/2022
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
8/27/2023
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
4/17/2022
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
7/31/2023
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
1/10/2021
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
5/29/2022
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
4/29/2022
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
2/22/2021
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
7/31/2023
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
8/24/2020
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
4/17/2022
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent

LigandBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)Copy SMILESCopy InChI

Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair

Target InfoPDB
UniProtKB/SwissProt
GoogleScholar

Ligand InfoPC cidPC sidSimilars

In Depth
Date in BDB:
8/27/2023
Entry Details
Copy BDB DOIUS Patent

Copy reaction URL